This clinical-stage biotech develops small-molecule therapies targeting NASH, obesity, and related metabolic diseases.

Good day, everyone, and welcome to Ascentage Pharma's 2025 Annual Results Earnings Call. [Operator Instructions] As a reminder, today's call is being recorded. Thank you for joining us. I will now ...

FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC) Selective CBP degrader program with ...

Q4 2025 Earnings Call March 25, 2026 8:30 AM EDTCompany ParticipantsJisong Cui - Co-Founder, Chairwoman & CEOXin Fu ...

We examine Bristol Myers Squibb’s pipeline strategy and therapeutic priorities in 2026, as it faces a major patent cliff in ...

A multinational research team led by researchers at Institute of Science Tokyo, RIKEN, and the University of Toronto has ...

Black Diamond Therapeutics (NASDAQ:BDTX) used a presentation at the 46th annual TD Cowen Healthcare Conference to highlight ...

Detailed price information for Skye Bioscience Inc (SKYE-Q) from The Globe and Mail including charting and trades.

The wait for Lionel Messi’s 900th goal continues. Messi – the Argentine World Cup champion – entered the match sitting on 899 goals for club and country in his career, hoping to join rival Cristiano ...